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 Abstract
Objectives: The role of 18F-FDG (18F fluorodeoxyglucose) PET/CT** (Positron emission tomography) in the 
diagnosis, treatment and follow up of benign and malignant ovarian tumors had been investigated previously. The 
objective of the following study was to evaluate the predictive value of PET/CT in benign and malignant ovarian 
tumors and compare with computerized tomography and post-operative pathology.
Materials and methods: In this retrospective study, a total of sixty nine cases with benign or malignant pelvic 
masses underwent laparotomy at our clinic. Postoperative pathology of the patients was recorded and PET/CT 
results were compared with ultrasonography, computerized tomography and postoperative pathology. 
Results: The ROCs and AUCs values four predictors were shown in Figure 1. The AUCs (95 % CI) values calculated 
for CA 125, ultrasonography (USG), PET/CT and CT were as follows: 0.855(0.752-0.958), 0.703(0.540-0.866), 
0.681(0.514-0.848) and 0.631(0.463-0.799) respectively. CA 125 has the highest AUC value in order to predict 
the malignant potential of the patient. USG has the highest AUC value between the imaging techniques, following 
PET/CT and CT. 
Conclusion: According to this study, among four modalities that distinguish malignant potential preoperatively; 
CA125 is the best parameter. USG and PET provide similar benefits in detecting malignant ovarian masses 
preoperatively. Both of these parameters are superior to CT. Combination of CA125, USG and PET/CT may be 
useful in detecting malignant ovarian masses preoperatively, resulting in less invasive surgeries. 
** 18F-FDG (18F fluorodeoxyglucose) PET/CT will be used as the PET/CT, later in this article.
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Introduction
Preoperative	 imagining	 is	 one	 of	 the	 most	 important	
diagnostic	steps	in	oncology.	Computerized	tomography	(CT)	and	
magnetic	resonance	imagining	(MRI)	are	both	used	in	evaluating	
abnormal	masses,	but	they	fail	to	supply	data	about	the	metabolic	
process	of	the	lesion	[1].	
PET/CT	imagining	technique	offers	an	opportunity	to	detect	
active	 metabolic	 processes	 and	 morphological	 features	 of	 the	
tissues	in	a	single	examination	[2].	The	most	commonly	used	area	
of	PET/CT	imagining	is	oncology,	and	depends	on	the	different,	
increased	use	of	the	18F-FDG	by	cancer	cells	when	compared	with	
the	normal	cells	[3].	Kubato	et	al	reported	that	the	macrophages	
of	tumor	cells	have	a	high	uptake	of	18F-FDG	[4].
In	patients	with	ovarian	carcinoma,	PET/CT	imagining	can	
be	 used	 for	 staging,	 prognosis	 and	 diagnosis	 of	 recurrence	 [5-
8].	 	 In	 a	 study	 by	Saif	 et	 al.,	 reported	 that	 PET/CT	 imagining	
can	be	used	as	an	initial	method,	staging,	treatment	monitoring	
and	 radiotherapy	 planning	 [9]. To	 the	 best	 of	 our	 knowledge,	
only	 two	studies	so	far	have	compared	 the	diagnostic	accuracy	
of	 ultrasonography,	 CT	 and	 MRI [11],	 and	 Kurtz	 et	 al.,	 also	
compared	these	modalities	with	postoperative	histopathology	in	
ovarian	masses [11].
In	 this	 study,	 the	 authors	 aimed	 to	 evaluate	 the	 diagnostic	
accuracy	 of	 CA125,	 USG,	 CT,	 	 PET/CT	 and	 postoperative	
histopathology	 of	 the	 patients	with	 ovarian	 tumors	 operated	 at	
our	clinic.
Materials and methods
We	performed	 this	 retrospective	 study	 at	Dicle	University	
School	of	Medicine,	Department	of	Obstetrics	and	Gynecology,	
Division	 of	 Gynecological	 Oncology,	 from	 January	 2006	 to	
December	2009.	Dicle	University	Hospital	is	a	tertiary	research	
and	education	hospital	in	southeastern	Turkey.	This	is	a	referral	
center	of	gynecological	oncology	that	most	of	the	patients	were	
referred	to	from	the	surrounding	health	centers.	
A	total	of	sixty	nine	patients	with	benign	or	malignant	pelvic	
masses	 subjected	 to	 laparotomy	were	 included	 into	 this	 study.	
The	clinical	characteristics	of	the	enrolled	patients	are	presented	
in	Table	1.	
Forty	eight	(69.5	%)	of	 the	patients	had	malignant	ovarian	
tumors	 and	 twenty	 one	 (30.5	 %)	 had	 benign	 ovarian	 tumors.	
The	initial	evaluation	of	the	patients	included	gynecological	and	
obstetric	 history,	 systemic	 examination,	 complete	 blood	 count,	
tumor	markers,	 chest	x	 ray,	ultrasonography,	CT	and	 	PET/CT	
imagining.	
Conventional US Protocol1. 
The	system	used	was	the	Voluson	730	PRO	Real	Time	4D	
imaging	 technology	 (GE	 Medical	 System,	 Milwaukee,	 USA).	
This	 device	 has	 transabdominal	 and	 transvaginal	 probes	 with	
maximal	 frequencies	of	2	and	7	MHz,	 respectively.	 It	 also	has	
power	and	color	Doppler	capability.	Morphological	evaluation	of	
the	ovarian	masses	for	benign	and	malignant	differentiation	was	
performed	using	the	inner	wall	structure,	wall	thickness,	presence	
of	 septa	 and	 their	 thickness	 and	 echogenicity	 according	 to	 the	
Sassone	criteria [12]	and	Doppler	velocimetry.	
CT Protocol2. 
The	 systems	 used	 for	 CT	 scanners	 were	 4-slice	 MDCT	
(Somatom,	 Volume	 Zoom,	 Siemens,	 Germany)	 as	 follows:	
4-slice	 MDCT:	 collimation	 2.5mm;	 table	 movement	 10mm;	
pitch	1,	120	kV,	60-100	mAs,	with	intravenous	contrast	medium	
administration;	3	mm	slices	of	abdomen	were	obtained.
PET-CT Protocol3. 
PET	scanning	was	performed	with	a	whole	body	PET	system	
(Siemens	Biograph	6	LSO).	 It	 takes	60	minutes	 to	prepare	 the	
patient	(fasting	6	hours	prior	to	the	examination,	200	Mbq	FDG,	
20	mg	furosemid	iv)	and	then	scanning	of	the	whole	body	(takes	
43	minutes),	including	the	abdomen	and	pelvis,	was	performed 
[13].   
 Streszczenie
Cel pracy: Rola 18F-FDG PET w diagnozowaniu łagodnych i złośliwych guzów jajnika w diagnozowaniu oraz 
obserwacji po leczeniu była już tematem badań. Celem tej pracy jest ocena wartości predykcyjnej PET/CT w 
łagodnych i złośliwych guzach jajnika i porównanie tej metody z tomografią komputerową i pooperacyjnym wynikiem 
histopatologicznym.
Materiał i metody: Badanie retrospektywne przeprowadzono na grupie 69 pacjentek z łagodną bądź złośliwą 
zmianą w miednicy mniejszej, które poddano laparotomii w naszej klinice. Wynik pooperacyjny histopatologiczny 
porównano z wynikiem badania PET/CT, USG, tomografią komputerową.
Wyniki: Obliczone wartości AUC (95%CI) dla CA125, USG, PET/CT i tomografii komputerowej wyniosły 
odpowiednio: 0,855 (0,752-0,958), 0,703 (0,540-0,866), 0,681 (0,514-0,848) i 0,631 (0,463-0,799). Marker 
CA125 miał najwyższą wartość AUC dla przewidywania złośliwych zmian. USG miało najwyższą wartość AUC 
wśród technik obrazowania, następnie PET/CT i tomografia komputerowa.
Wnioski: Według tego badania, spośród analizowanych czterech metod przedoperacyjnego prognozowania 
charakteru guza, CA125 jest najlepszym parametrem. USG i PET mają podobną siłę wykrywania zmian złośliwych 
przed operacją. Kombinacja badania CA125, USG i PET/CT może być przydatną metodą wykrywania złośliwych 
guzów jajnika przed operacją i wykonywania mniej inwazyjnych operacji.    
Słowa	kluczowe:	pozytonowa emisyjna tomografia komputerowa / 
             / tomografia komputerowa / nowotwory jajnika, łagodne, złośliwe / 
              / wartość predykcyjna /  
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The	operation	types	included	total	abdominal	hysterectomy,	
bilateral	 salpingo-oophorectomy,	 peritoneal	 washing	 fluid	
samples,	 infracolic	 omentectomy,	 pelvic	 and	 paraaortic	 lymph	
node	 dissection,	 and	 appendectomy	 for	 ovarian	 cancer	 (if	 the	
frozen	 section	 revealed	 benign,	 pelvic	 mass	 extirpation	 was	
performed).	
The	post	operative	histopathological	diagnosis	of	the	cases	
were	recorded	and	compared	with	preoperative	CT	and	PET/CT	
results.	
Statistical analysis
Means	 and	 standard	 deviations	 (SD)	 were	 calculated	 for	
continuous	 variables.	 The	 independent	 sample	 t-test	 was	 used	
to	evaluate	associations	between	the	categorical	and	continuous	
variables.	All	variables	were	included	in	the	backward	stepwise	
procedure.	 Two-sided	 p-values	 were	 considered	 statistically	
significant	at	p	<0.05.	Statistical	analyses	were	carried	out	using	
the	statistical	packages	for	SPSS	15.0	for	Windows	(SPSS	Inc.,	
Chicago,	IL,	USA).
The	sensitivity,	specificity,	accuracy,	positive	predictive	value,	
and	negative	predictive	value	of	discrete	variables,	such	as	PET/
CT	and	USG/CT,	were	calculated	on	the	basis	of	postoperative	
histopathology.	 Differences	 in	 cumulative	 sensitivity	 and	
specificity	 between	 the	 imaging	 modalities	 were	 tested	 for	
statistical	 significance	 using	 the	McNemar	 test.	 In	 addition,	 to	
compare	 the	 diagnostic	 accuracy	 of	 the	 imaging	 procedures,	 a	
receiver-operating-characteristic	curve	(ROC)	analysis	using	the	
method	of	Metz	 [14]	was	performed,	the	ROCs	and	AUCs	values	
were	determined	for	PET/CT	,	USG,	CT	and	CA	125.	AUC	value	
is	known	to	have	the	ability	of	distinguishing	malignant	potential	
of	the	patients.
Results
A	total	of	sixty	nine	cases	with	benign	or	malignant	pelvic	
masses	were	 subjected	 to	 laparotomy	at	our	 clinic.	Forty	 eight	
(69.5%)	of	the	patients	had	malignant	ovarian	tumors	and	twenty	
one	(30.5%)	cases	had	benign	ovarian	tumors.	The	mean	age	of	
the	subjects	was	57,2±14,0	years.	Postoperative	pathology	of	the	
cases	is	presented	in	Table	II.	
Thirty	 six	 (42.8%)	 of	 the	 cases	 turned	 out	 to	 be	 serous	
cystadenocarcinoma,	 eight	 (9.5%)	 borderline	 ovarian	 tumor,	
five	 (5.9%)	 clear	 cell	 carcinoma,	 three	 (3.5%)	 mucinous	
cystadenocarcinoma	and	four	(4.7	%)	other	types	(dysgerminoma,	
granulosa	 cell	 tumor,	 immature	 teratoma	 and	 yolk	 sac	 tumor).	
The	benign	histopathologies	were	seven	(8.3%)	cases	of	serous	
cystadenoma,	two	(2.3%)	mucinous	cystadenoma	and	five	(5.9%)	
other	types	(benign	cystic	teratoma	and	abscess). 
In	 this	 study	 the	 gold	 standard	 to	 detect	 the	 malignity	
were	 postoperative	 histopathological	 findings	 and	 diagnosis	 of	
pathological	 specimen	 (P.S).	 Eight	 patients	 according	 to	USG,	
seven	 according	 to	 PET/CT	 and	 four	 according	 to	 CT	 were	
assessed	to	be	malignant	preoperatively	but	all	of	these	patients	
were	found	to	have	benign	histopathology.	
Table I. The clinical characteristics of the patientsgo. 
Table II. Postoperative histopathology of the patients. 
Table III. Comparison of PET/CT with ultrasonography and tomography results with postoperative histopathological outcomes. 
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The	true	positive	(TP),	true	negative	(TN),	false	positive	(FP),	
false	 negative	 (FN),	 sensitivity,	 specificity,	 positive	 predictive	
value	(PPV),	negative	predictive	value	(NPV)	and	accuracy	were	
calculated	 and	 the	 diagnostic	 power	 of	 the	 imaging	modalities	
was	compared.	(Table	III).	
The	accuracy	of	USG	and	PET/CT	was	 the	 same	 (81.6%)	
and	both	was	higher	than	CT.	The	ROCs	and	AUCs	values	four	
predictors	were	shown	in	Figure	1.	
The	 AUCs	 (95%	 CI)	 values	 calculated	 for	 CA	 125,	
USG,	 PET/CT	 and	 CT	 were	 as	 follows:	 0.855(0.752-0.958),	
0.703(0.540-0.866),	0.681(0.514-0.848)	and	0.631(0.463-0.799),	
respectively.	CA	125	has	the	highest	AUC	value	in	order	to	predict	
the	malignant	potential	of	the	patient.	USG	has	the	highest	AUC	
value	 between	 the	 imaging	 techniques,	 following	PET/CT	 and	
CT.	
Discussion
PET	has	an	 increasing	role	 in	 the	diagnosis,	 treatment	and	
monitoring	of	malignant	diseases.	The	first	PET	scanner	was	used	
in	 1998.	 Following	 the	 development	 of	 PET	 imaging	with	 the	
fluorine	18	(18F)-labeled	glucose	analogue,	18F	fluorodeoxyglucose	
(FDG)	started	to	be	used [15].		
Adnexal	masses	are	common	problems	of	all	women	of	all	
ages.	The	etiology	of	adnexal	masses	remains	unknown.		
Adnexal	masses	in	adolescents	and	women	of	reproductive	
age	are	most	commonly	functional	or	benign	neoplastic	ovarian	
masses,	whereas	the	risks	of	malignant	ovarian	tumors	increase	
with	age [16].	
In	 spite	 of	 new	 chemotherapeutics,	 operative	 techniques	
and	other	auxiliary	treatments,	the	5-year	survival	is	still	low	in	
malignant	ovarian	tumor.	Therefore,	early	diagnosis	and	therapy	
are	important	to	prolong	the	life	and	improve	the	life	quality	of	
epithelial	ovarian	cancer	cases.	Imaging	techniques	have	played	
an	 important	 role	 in	 the	 clinical	 management	 of	 patients	 with	
ovarian	 cancer.	 It	 is	 important	 for	 tumor	 detection,	 staging,	
treatment	planning,	and	follow-up [17].
In	this	study,	the	authors	wished	to	evaluate	and	report	their	
clinical	experience	of	imaging	techniques	in	benign	and	malignant	
adnexal	masses.	A	total	of	sixty	nine	patients	with	pelvic	masses	
subjected	to	laparotomy	were	included	to	this	study.	The	clinical	
characteristics	of	the	patients	were	presented	in	Table	I.		
Sixty	 nine	 cases	 with	 benign	 or	 malignant	 pelvic	 masses	
subjected	 to	 laparotomy	 at	 our	 clinic.	 Forty	 eight	 (69.5%)	 of	
the	 patients	 were	 malignant	 ovarian	 tumors	 and	 twenty	 one	
(30.5%)	 benign	 ovarian	 tumors.	 The	 initial	 evaluation	 of	 the	
patients	 included	 gynecological	 history,	 systemic	 physical	
examination,	complete	blood	count,	tumor	markers,	chest	x	rays,	
ultrasonography,	CT	and	PET/CT	imagining.	
 
Figure 1. ROC curve for detecting malignancy by postoperative histopathology.  
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The	 AUCs	 (95%	 CI)	 values	 calculated	 for	 CA	 125,	
USG,	 PET/CT	 and	 CT	 were	 as	 follows:	 0.855(0.752-0.958),	
0.703(0.540-0.866),	0.681(0.514-0.848)	and	0.631(0.463-0.799),	
respectively.	CA	125	has	the	highest	AUC	value	in	order	to	predict	
the	malignant	potential	of	the	patient.	USG	has	the	highest	AUC	
value	 between	 the	 imaging	 techniques,	 following	PET/CT	 and	
CT.	
Many	previous	reports	discussed	the	application	of	PET/CT	
in	malignant	diseases.	Ng	et	al. [17] reported	their	experience	of	
PET/CT	usage	in	oral	cavity	squamous	cell	carcinoma.	Blodgett	
et	 al.	 [15]	 also	described	 the	 cancers	where	PET/CT	was	used	
in	 the	 following	 cases:	 brain	 tumors,	 head	 and	 neck	 tumors,	
thyroid	carcinoma,	lung	cancer,	esophageal cancer,	breast	cancer,	
colorectal	cancer,	lymphomas,	melanoma	and	also	gynecological	
malignancies.	 Iagaru	et	al. [18] conducted	a	 retrospective	study	
and	reported	their	experience	of	forty	three	women	with	ovarian	
cancer.	They	 found	 that	PET/CT	 imaging	 is	 a	 good	diagnostic	
tool	 for	 both	 identification	of	 residual/recurrent	 ovarian	 cancer	
and	distant	metastases	localization.	
In	 this	study,	by	using	 the	pathology	results	 (79.1%	of	 the	
patients)	or	clinical	 follow-up	(20.9%	of	 the	cases)	as	 the	gold	
standard,	 they	 found	 PET-CT	 to	 have	 an	 overall	 per	 patient	
sensitivity	 of	 88.4%	 (95%	 CI:	 75.1–95.4)	 and	 specificity	 of	
88.2%	(95%	CI:	64.4–97.9)	for	detection	of	ovarian	cancer.	
In	 other	 studies,	 in	 the	 primary	 diagnosis	 and	 staging	 of	
ovarian	cancer,	Hubner	et	al	[19]	reported	a	positive	predictive	
value	of	86%	and	a	negative	predictive	value	of	76%	and	Schroder	
et	 al [20]	 reported	overall	 accuracy	of	90%,	with	 sensitivity	of	
96%	and	negative	predictive	value	of	75%.	
In	our	study,	PET/CT	imaging	was	found	to	have	accuracy	of	
81.6%,	with	sensitivity	of	92.45	%	and	negative	predictive	value	
of	84.48%.	
Conclusion
In	 conclusion,	 PET-CT	 imaging	 is	 a	 useful	 imaging	
technique,	especially	in	oncology.	According	to	this	study,	it	has	
no	preponderance	to	USG.	With	the	combination	of	CA125,	USG	
and	PET-CT	better	outcomes	may	be	achieved.	
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